Other substances

Ozanimod

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
Oral drug repositioning candidates and synergistic remdesivir combinations for the prophylaxis and treatment of COVID-19 Preprint In vitro Screening	HeLa-ACE2 cells			Jun/16/2020

AI-suggested references

Link	Publication date
Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.	Feb/28/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04405102	COVID-19 Ozanimod Intervention Study	Recruiting	Phase 2	Sep/16/2020	Jan/01/2024
Alternative id - 2021-3474 Interventions - Drug: Ozanimod\|Other: Standard of care Study type - Interventional Study results - No Results Available Locations - Hôpital de la Cité-de-la-Santé (CISSS de Laval), Laval, Quebec, Canada\|Hôpital Santa Cabrini Ospedale (CIUSSS EMTL), Montréal, Quebec, Canada\|Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 48 Age - 18 Years to 85 Years (Adult, Older Adult) Outcome measures - Daily Patient progression assessed with the World Health Organization-adapted 6-points ordinal scale\|The mean oxygen flow required to maintain the oxygen saturation (SpO2) target at 92%\|Rate of non invasive ventilation (NIV) / high flow nasal therapy (HFNT) use\|Rate of intubation\|Ventilator-free and oxygen-free days at day 28\|Rate of ICU admission/length of stay/mortality\|Severity index measurement